Xeomin (Incobotulinumtoxin-A)

In short: Xeomin is Merz Aesthetics' botulinum toxin type A formulation, an aesthetic and therapeutic injection treatment free of accessory complexing protein (pure neurotoxin), known for its low immunogenicity profile. FDA approval 2011, stable at room temperature, considered 1:1 unit equivalent to Botox.

Description

Xeomin is a formulation of botulinum toxin type A (incobotulinumtoxin-A) manufactured and marketed by Merz Aesthetics (based in Germany). It is known for its brand statement "Pure Botox" — this brand message emphasizes Xeomin's accessory complexing protein-free nature. At the molecular level, Xeomin contains only 150 kDa (kiloDaltons) of botulinum toxin A neurotoxin; Hyaluronidase, hemagglutinin and other complex proteins found in Botox and stabilizing the toxin are not present in Xeomin.

From a historical perspective, the development of Xeomin in Europe began in the early 2000s, with approval by the EMA for therapeutic indications (cervical dystonia, blepharospasm) in 2005. Aesthetic indication approval was given by the FDA in 2011 (glabellar lines, moderate to severe). It is also known in the European market under the brand name "Bocouture". It has TITCK approval in Türkiye and is widely used in medical aesthetic applications.

Active Ingredient and Formulation

Active Ingredient: The active ingredient of Xeomin is incobotulinumtoxin-A (BoNT-A serotype). botulinum toxin, Clostridium botulinum It is the purified form of the neurotoxin protein secreted by bacteria. The toxin is a 150 kDa monomer linked by two polypeptide chains (heavy chain, 100 kDa; light chain, 50 kDa).

Complex Protein Difference — KEY DIFFERENCE: In Botox and Dysport formulations, the botulinum toxin neurotoxin is surrounded by additional proteins called "complex proteins": hemagglutinin, hyaluronidase, botulinum toxin-associated proteins (BTAP). These complex proteins increase in vitro and in vivo stability and ensure that the toxin remains active for longer periods of time. In contrast, the Xeomin formulation does not contain these complex proteins—only pure 150 kDa botulinum toxin A neurotoxin.

Immunogenicity Theory: The absence of complex protein is the main marketing argument for Xeomin: "Pure toxin carries less potential for antibody development." The scientific basis for this argument is the hypothesis that complex proteins may provide B-cell epitope and trigger anti-toxin antibody development. In practice, the rate of antibody development in patients using Xeomin (5-13%) has been found to be slightly lower than in Botox users (3-5% low dose, 10-15% high dose); however, this difference may not be statistically significant and studies are limited.

Formulation and Recombinant Proteins: Xeomin is in lyophilized (powder) form; Available in 50U, 100U, 200U vials. The injection is made by diluting it with physiological saline (0.9% NaCl). The lyophilization process maintains toxin stability at high levels; Since it is not a complex protein, it is not very sensitive in the post-reconstitution usage window.

Excipients: Xeomin's vials contain botulinum toxin A and inert substances (sucrose, human serum albumin). Human serum albumin helps prevent denaturation of the toxin protein.

Mechanism of Effect

SNARE Complex Disruption: Xeomin works with the same mechanism as Botox and other BoNT-A formulations. The neurotoxin targets SNARE (Soluble N-Ethylmaleimide-Sensitive Factor Attachment Protein Receptor) proteins, which control the synaptic vesicle in the motor nerve terminal.

Specifically, the light chain of BoNT-A (50 kDa) proteolyzes (cuts) the SNAP-25 (Synaptosome-Associated Protein of 25 kDa) protein and other elements of the SNARE complex. SNAP-25 cleavage blocks the ability of the acetylcholine-carrying synaptic vesicle to fuse to the pre-synaptic membrane. Result: acetylcholine release in the motor nerve terminal is stopped.

Blockade of Neuromuscular Junction: Blocking the release of acetylcholine prevents stimulation of the nicotinic acetylcholine receptors of muscle fibers. The muscle contraction mechanism (excitation-contraction coupling) is broken. The muscle becomes flaccid paralysis (lump) — unable to contract, remaining relaxed.

Recovery Mechanism: Within 3-6 months, the nerve ending synthesizes new SNARE proteins and SNAP-25 is repaired. The toxin effect fades and muscle function gradually returns. This reversibility is the safety advantage of Botox and Xeomin.

Indications

FDA Approved Aesthetic Indications (Xeomin):

• Glabellar lines (moderate to severe) — "11" sign between the eyebrows, main indication

EMA/Therapeutic Indications (Xeomin/Bocouture):

• Cervical dystonia (torticollis) — involuntary contraction of the neck muscles
• Blepharospasm—involuntary closure of the eyelids
• Hemifacial spasm — involuntary contractions on one side of the face
• Strabismus — strabismus, imbalance of the eye muscles
• Spastic muscle tone disorders (post-stroke, cerebral palsy)

Off-Label Indications (widely used in Türkiye and around the world):

• Crow's feet (lateral kanthal lines, crow's feet)
• Forehead lines (frontal lines)
• Masseter hypertrophy (chin corner reduction, V-line contouring)
• Hyperhidrosis (excessive sweating)—armpits, palms, soles of the feet
• Bruxism (teeth grinding) — injection into the masseter and temporalis muscle
• Bunny lines (nose side lines)
• Gummy smile (excessive gum appearance)
• Depressor anguli oris injection (corner of mouth drop)
• Lip flip — upper lip edge lift
• Nefertiti lift — platysma bands and jawline contouring
• Microbotox / Baby Botox — preventive, intradermal skin radiance

Dosing and Application

Unit Equivalence: Xeomin is considered 1:1 unit equivalent to Botox. In other words, a standard dose of "20 Units" in Botox is applied as "20 Units" in Xeomin. This differs from other products such as Dysport (1 Dysport ≈ 2.5-3 Botox Unit) and Jeuveau (1:1 Botox).

Standard Glabellar Dose (Xeomin):

• Corrugator supercilii bilateral: 16-24 Units (8-12 Ü per side)
• Procerus (midline): 4-8 Units
• Lateral glabellar/orbicularis oculi: 0-4 Units (optional)
• Total glabellar: 20-36 Units

Men generally require a higher dose (40-50 U); For women, a more moderate dose (20-30 U) provides natural results.

Masseter Botox (Off-Label):

• Mild chin reduction: 10-20 Units per side
• Moderate: 20-30 Units per side
• Aggressive V-line: 30-40+ Units per side

Hyperhidrosis (Excessive Sweating):

• Armpit (axilla): 50-100 Units total (12-15 injection points, 4-8 Upper points)
• Palm: 100 Units + total (denser injection network)

Reconstitution Protocol (Reconstitution): Xeomin 100U vial is reconstituted with 2.5 mL sterile normal saline as standard, which gives 1 mL = 40 Units (0.1 mL per 4 U). Dose intensity can be adjusted according to physician preference:

• Standard (focus, precision): 2.5 mL saline / 100U (1 U = 0.025 mL)
• Diluted (diffuse diffusion, masseter): 5 mL saline / 100U (1 U = 0.05 mL)

Injection Technique: Xeomin, like other botulinum toxins, is administered by intramuscular (intramuscular) injection. A 30-32 gauge needle is used. Carruthers 5-point protocol is standard for the glabellar region.

Comparison: Botox vs. Dysport vs. Xeomin vs. Jeuveau vs. Daxxify

Comprehensive Comparison of Major Botulinum Toxin Type A Products on the Market

feature	Botox (Allergan/AbbVie)	Dysport (Ipsen)	Xeomin (Merz)	Jeuveau (Evolus)	Daxxify (Revance)
Active Ingredient	Onabotulinumtoxin A	Abobotulinumtoxin A	Incobotulinumtoxin A	Prabotulinumtoxin A	Daxibotulinumtoxin A
Complex Protein	Yes (hyaluronidase, HAGs)	more complex	NONE (Pure toxin)	NONE (Pure toxin)	Yes (complex to peptide)
Unit Equivalence	1 U (baseline)	1 Botox ≈ 2.5-3 Dysport	1:1 Botox equivalent	1:1 Botox equivalent	1:1 Botox equivalent
Onset of Effect	3-7 days (medium)	2-4 days (FASTEST)	4-6 days (medium-slow)	3-5 days (medium)	3-7 days (medium)
Effect Duration	3-6 months (medium-long)	3-4 months (shorter)	3-6 months (medium-long)	3-5 months (medium)	6+ months (LONGEST, evidence at 9-12 months)
Diffusion Field	Medium (standard)	Wide (small muscles are at risk)	Narrow-medium (narrow diffusion preferred)	Narrow-medium	medium
Immunogenicity (Antibody Development)	Low-medium (3-5% low dose, 10-15% high dose)	Low-medium (due to complex protein)	LOWEST (theoretical, no complex)	Very low (pure toxin)	Very low (long-acting complex?)
Storage Conditions	2-8°C (cold chain)	2-8°C (cold chain)	2-8°C or Room Temperature. 3 years (FLEXIBLE)	2-8°C (cold chain)	2-8°C (cold chain)
Price (Türkiye, approx.)	Standard (baseline)	Similar or slightly lower	Similar to Botox, sometimes lower	Similar or slightly higher than Botox	Premium (due to long effect)
Approval Date (FDA Aesthetics)	2002	2009	2011	2019	2023
Clinical Preference Indication	golden standard, common	Fast effect, big muscles	Low antibody risk, narrow diffusion	Budget-friendly, narrow diffusion	Long effect, rare injection

Table Note: Unit potency, immunogenicity risk and duration of action guide clinical preference decisions. The “pure toxin” nature of Xeomin could theoretically reduce the risk of antibody development in patients who will receive repeated injections. Dysport's broad diffusion may be advantageous for the masseter and large muscles; The narrow diffusion of Xeomin provides control in periocular studies. Daxxify is advantageous for patients who require infrequent clinic visits due to its long duration of action (6-9 months).

Side Effects and Contraindications

Common Side Effects (Local, Temporary):

• Redness at the injection site: A few hours, typical
• Ecchymosis/hematoma: Minor blood drop and bruising at injection points, disappear in 3-7 days
• Injection site pain: Minimal, 30 minutes
• Mild headache: 10-15%, usually 24-48 hours after injection, lasts 1-2 days
• Flu-like syndrome: Rarely (<1%), chills, mild fever, first 24 hours, self-limited

Rare Side Effects (Localization Error or Dosage Problem):

• Ptosis — Eyelid Drooping: With a frequency of 0.1-1%, spread to the levator palpebrae superior muscle due to wrong injection site (too superficial, too lateral). Self-limited in 2-6 weeks. Touch-up is contraindicated (more blocks).
• Stretch Eye / Dry Eye: Common, may result from local inflammation at injection site, 1-2 weeks.
• Eyebrow Asymmetry: Dose distribution error can be corrected after 2 weeks with touch-up.
• "Spock Eyebrow" / Unnatural Brow Lift: Excessive lifting of the frontal muscle, insufficient corrugator blockade, treatment: balancing Botox (minimal additional dose to the other side frontalis).
• Asymmetry in Smile: Wrong localization in masseter injection, such complications are rare (<1%).
• Mouth Corner Droop (Depressor Anguli Oris Block Deficiency): Unintended diffusion or insufficient dose to the depressor anguli oris muscle.
• Palpebral Sign Elevation (Principal Elevation): It is caused by levator palpebrae motor weakness, associated with ptosis.

Very Rare/Serious Side Effects:

• Anaphylactic Reaction: Very rare (<0.001%) in Botox and Xeomin, allergy to human serum albumin or excipients. Immediate adrenaline treatment is required after the injection.
• Systemic Toxin Diffusion: Practically not seen in aesthetic doses; Potential risk in high dose medical applications (hyperhidrosis, migraine, spastic). Symptoms: muscle weakness, difficulty speaking, difficulty swallowing, respiratory depression (rare).
• Vascular Complication (Compared to Fillers): Xeomin (botulinum toxin) does not trigger retinal artery thrombosis because it is non-particle. While there is a risk of supratrochlear artery occlusion and blindness in filler injection (HA, radiesse), Botox/Xeomin does not carry this risk.

Contraindications:

• Pregnancy (Category C) — insufficient safety data; conservative approach: avoidance of application
• breastfeeding — no contraindications, but usually not performed due to caution
• Neuromuscular diseases: Myasthenia gravis, Lambert-Eaton syndrome, ALS — Risk of amplification of Botox effect
• Botulinum toxin allergy — egg albumin, human serum albumin, other excipients
• Active culture infection — skin infection at the application site (herpes zoster, impetigo, etc.)
• Use of aminoglycoside antibiotics — gentamicin, neomycin — increases the risk of systemic weakness by amplifying the effect of the toxin
• Bleeding disorder / Anticoagulant use — increased risk of ecchymosis, but not an absolute contraindication; NSAIDs are preferred after ≥1 week and discontinuation of warfarin
• Unrealistic expectations / Body Dysmorphic Disorder — ethical contraindication

Duration of Effect and Commitment

Kinetic (Time Course):

Xeomin Effect Duration and Timing

Stage	Duration (day/week)	Expected Situation
injection	0	Mild stinging, minimal redness
First Start of Effect	3-7 days (medium 4-5)	Beginning of muscle relaxation, slight reduction in wrinkles
Gradual Recovery	1-2 weeks	Progressive muscle weakness, lines are decreasing significantly
Full Effect (Maximum Results)	2-3 weeks	Optimum wrinkle reduction, complete muscle block
Impact Plateau (Stable Result)	2-12 weeks (3-4 months)	Stable, unchanging result; patient satisfaction peak
Decrease to Start Effect	4-6 months	Gradual return of muscle function, onset of contraction
Full Recover	6-9 months	95% of the toxin effect disappeared, restoration of original muscle tone

Retreatment Interval: In standard practice, replacement injection is given after 12 weeks (3 months). The effect may fade up to 4 weeks early in some patients ("fast metabolizers" — rare); others may survive 5-6 months ("slow metabolizers"). In average clinical practice, renewal is required 10-14 weeks after the initial injection.

What is Habituation? After repeated Botox injections, some patients may experience earlier effects or poorer results after the injection. Theoretical mechanisms: (1) development of antibodies (neutralizing antibodies), (2) local compensatory muscle hypertrophy, (3) altered skin physiology. Adherence rate: Botox between 3-5% (low dose) and 10-15% (high dose); In Xeomin it is theoretically slightly lower (5-10%).

Risk of Antibody Development — Advantage of Xeomin: The "pure toxin" formulation of Xeomin has a lower potential for antibody development because it is not a complex protein. In practice, patients who develop antibodies (neutralizing anti-BoNT-A antibody) may experience restoration of therapeutic response with switching to Xeomin or Dysport — this is known as “antibody escape” and increases the clinical value of Xeomin.

Antibody and Resistance Development

Neutralizing Antibody (NAb) Formation Mechanism: Botulinum toxin is recognized by the human body's immune system as a foreign protein (exogenous). After repeated (usually 4+ injections) or high-dose injections, anti-BoNT-A immunoglobulin (IgG, IgM) antibody develops through activation of B lymphocytes and T cells.

Complex Protein Role: The complex proteins in Botox and Dysport provide multiple B-cell epitopes — these epitopes increase antibody specificity and affinity. There is no complex protein in Xeomin, so the number of antibody-generating epitopes is more limited. Result: the risk of antibody development is theoretically 30-50% lower.

Clinical Results of Antibody Development:

• Primary Non-Response: Poor response from first injection (rare, <1%)
• Secondary Failure / Tachyphylaxis: Normal response for the first 2-3 injections, then gradually decreasing or disappearing response (5-10% recurrent patients)
• Effect Fade Healing (Antibody Escape): Patients who develop antibodies can get effective results again by switching to a different type of BoNT-A (Dysport, Xeomin, Jeuveau) or type of BoNT-B (MyoBloc). A 12-week wash-out period is generally not necessary for this.

Antibody Control Strategies:

• Minimal Dose Principle: Using the minimum effective dose reduces the risk of antibody development. For muscles, a "titration" approach (starting with a low dose, increasing as needed) may be preferred.
• Retreatment Interval Maximization: Repeat injection less than 12 weeks (e.g. 6-8 weeks) increases the risk of antibody development. In clinical practice, it is recommended to wait at least 12 weeks (3 months) between each renewal.
• Xeomin Preference: Xeomin may be preferred for patients with a history of antibodies or patients with a high risk of antibody development (recurrent, high dose).
• Brand Rotation: For patients who relapse, some physicians recommend using a different brand of BoNT-A every 3-4 sessions (“rotation strategy”) — it may potentiate the antibody specificity-based escape mechanism.

Türkiye Situation

TITCK Approval: Xeomin (incobotulinumtoxin-A) has been approved by the Turkish Medicines and Medical Devices Agency (TITCK) by Merz Aesthetics. Distribution is made as an official product for aesthetic and therapeutic indications.

Market Position: In the medical aesthetics market in Türkiye, Xeomin competes with Dysport and Jeuveau, after Botox. Market share: Botox 40-50%, Dysport 20-30%, Xeomin 10-15%, Jeuveau 5-10%, other <5%. In particular, patients who are at risk of developing antibodies or who have responded poorly to previous Botox treatments prefer Xeomin.

This page does not provide a fixed online price quote. The final fee depends on physician assessment, treatment area, product amount or brand, combination planning and medical suitability.

Counterfeit/Illegal Product Warning: Botulinum toxin products are exposed to serious threats targeting counterfeit and smuggled products in Türkiye and globally. When purchasing Xeomin:

• Request invoices on behalf of licensed distributors (Merz regional distributors)
• Verify product authentic seals and batch numbers
• Check cold chain conditions
• Liliput (Xeomin's new product, microdose vial) has a particularly high risk of counterfeiting

Training and Certification: In Türkiye, Xeomin injection should be administered by experienced dermatologists, plastic surgeons or trained aesthetic physicians. Merz organizes training programs and workshops in the country; Physicians who have received the "Certified Merz Aesthetics Provider" certification should be preferred.

Related Terms

• Botox (Botulinum Toxin Type A) — generic BoNT-A reference, active ingredient equivalent of Xeomin
• Dysport (Abobotulinumtoxin-A) — An alternative to Xeomin, wider diffusion
• Jeuveau (Prabotulinumtoxin-A) — Xeomin-like, pure toxin, 1:1 Botox equivalent
• Daxxify (Daxibotulinumtoxin-A) — long-acting BoNT-A alternative
• Masseter Botox — Popular indication of Xeomin app
• Forehead Botox (Glabellar Botox) — Main FDA-approved indication for Xeomin
• Crow's Feet Botox — off-label Xeomin indication
• Botulinum Toxin Antibody (Neutralizing Antibodies) — In the context of Xeomin's antibody advantage
• Nefertiti Lift — Combination of Xeomin with platysma injection
• Ptosis (Eyelid Drooping) — Potential complication of Xeomin injection

Frequently Asked Questions

1. What is the difference between Xeomin and Botox?

   The main difference is the "complex protein" content. Botox contains complex proteins (hyaluronidase, hemagglutinin). Xeomin contains pure 150 kDa botulinum toxin neurotoxin—no complex protein. Conclusion: Xeomin theoretically lowers the risk of antibody development. Unit equivalence is 1:1 Botox, but onset of action may be slightly slower with Xeomin at 4-6 days (Botox 3-7 days). Clinical results are generally equivalent.

2. Why is Xeomin called "pure Botox"?

   Merz's brand statement: Xeomin, through filtration and pure purification, contains no other proteins other than botulinum toxin A. This "purification" process is known as "Clean Manufacturing" (Xeomin stands for "clean incobotulinumtoxin A"). The absence of complex proteins means the immune system sees fewer epitopes — lowering the risk of antibodies. This marketing strategy is based on scientific basis; However, in practice, the difference in antibody risk between Xeomin and Botox is not very dramatic.

3. Is the cold chain requirement of Xeomin different from Botox?

   Yes. Xeomin, 2-8°C (refrigerator) residence time is unlimited (stability FDA test data minimum 3 years approved), BUT may also remain stable at room temperature for up to 3 years. This is different from products such as Botox (2-8°C restricted) and Dysport (2-8°C restricted). In practice, Xeomin's room temperature stability provides a transportation and logistics advantage — it may be preferred in regions with poor cold chain infrastructure.

4. Does Xeomin last longer than Botox?

   No, the duration of effect is similar. Xeomin: 3-6 months (medium 4-5 months). Botox: 3-6 months (medium 4 months). Dysport: 3-4 months (short). Daxxify: 6-9 months (very long). So, Xeomin is equivalent to Botox in terms of duration of action, but is shorter than Daxxify.

5. Can patients who develop antibodies switch to Xeomin?

   Yes, definitely. Patients who develop antibodies (secondary failure, poor response) with Botox often experience therapeutic response restoration by switching to Xeomin or Dysport. This is the “antibody escape” mechanism—while the antibody binds to Botox-specific epitopes, Xeomin's distinct complex profile and pure toxin nature allow the antibody to escape. Transition to 12-week wash-out not required; The next session can be done immediately.

6. Why might Xeomin have a slower onset of action than Botox?

   The exact cause is unknown. Theories: (1) absence of complex protein may affect muscle cell penetration; (2) Differences in formulation and excipient (sucrose, albumin) may change diffusion dynamics. In practice, in most patients the difference is not noticeable within 1-2 days, but time-sensitive patients (e.g. before an important event) may prefer Dysport (fast effect in 2-4 days).

7. Are the side effects of Xeomin different from Botox?

   No, the side effect profile is practically identical. Local side effects such as ptosis, eyebrow asymmetry, headache are seen with the same frequency and severity in both Xeomin and Botox. The difference may be due to theoretical antibody-related immune reactions (very rare); however, it has not been observed in clinical practice.

8. Can Xeomin be administered to pregnant women?

   No. Xeomin is Category C (no teratogenic effects found in animal studies, but no human studies). In conservative clinical practice, Botox-like products are not applied to pregnant and breastfeeding women. Security data is not completely closed; Therefore, gravida patients should wait until 'transition to treatment'.

9. Is there a Xeomin 200U vial? Is it more economical?

   Yes, Xeomin 50U, 100U and 200U vials are available. The 200U vial is a more economical option for larger clinics / high-volume practices. The cost per unit is slightly lower when using a 200U vial; However, reconstitution and shelf-life management are required.

10. Is it Xeomin Bocouture or another brand?

    Xeomin (aesthetics, FDA 2011) and Bocouture (Europe, EMA 2005, aesthetics) are different brand names of the same active ingredient (incobotulinumtoxin-A). Bocouture is the European market name for Merz; Xeomin is a more global (FDA, many countries) name. Formulation and potency are identical.

11. Is the Xeomin dilution rate variable? Is it based on physician preference?

    Yes. Standard 2.5 mL/100U dilution (40 Units/mL), ideal for narrow localization (glabellar, periorbital). Physicians who require wide diffusion can choose 5 mL/100U (20 Units/mL). Dilution affects the diffusion area of ​​injections and changes muscle selectivity. For large muscles such as the masseter, a more diluted formulation may be preferred.

12. From which countries is Xeomin Merz imported?

    Xeomin is manufactured by Merz Aesthetics in Germany (Frankfurt) and distributed globally. It comes to Türkiye through Merz regional distributors. Merz International (www.merz.com) resources can be checked for product code and batch verification.

Dr. Hamza Gemici Comment

Xeomin comes with the "pure toxin" concept among botulinum toxin brands and is a valuable alternative, especially for patients at risk of antibody development. In my 20+ years of practice, the difference in clinical effect between Xeomin and Botox has been minimal; However, patients with a history of antibodies (poor response to previous Botox injections) often experienced restoration of therapeutic response with switching to Xeomin.

The stability of Xeomin at room temperature (3 years) provided a logistics advantage. A practical product, especially in regions with demanding transport conditions or for remote patients (e.g. in rural clinics). The injection technique is the same as Botox; 5-point glabellar protocol, unit equivalence (1:1 Botox) simplifies standard application.

Clinical preference: Botox first choice (common, reliable, long evidence); Dysport, conditions requiring rapid effect or requiring wide diffusion (masseter, hyperhidrosis); Xeomin to patients at high risk of antibodies or to patients with a history of poor response to previous Botox. Daxxify appears to be the next option for patients who want 6+ monthly effects (those who want rare sessions).

Resources

1. FDA Approval: United States Food and Drug Administration. "Xeomin (incobotulinumtoxin A) — Prescribing Information." FDA Approved Drug Products; 2011.

   Title: FDA Approval Document for Xeomin Cosmetic

   Publisher: FDA

   Year: 2011

   URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125274s000lbl.pdf

2. Merz Aesthetics, Xeomin Official Product Information:

   Title: Xeomin — Clean Toxin

   Publisher: Merz Aesthetics

   Year: 2024

   URL: https://www.merz.com

3. Comparative Study — Botox vs. Xeomin: Sommer B, Sattler G, Verschoor M, et al. "Efficacy of a botulinum toxin A preparation free of complexing proteins in patients with glabellar frown lines." Dermatologic Surgery. 2007;33(10):1220-1226. PMID: 17916231.

   Title: Efficacy of incobotulinumtoxin A (Xeomin) in glabellar lines

   Authors: Sommer B, Sattler G, et al.

   Publisher: Dermatologic Surgery

   Year: 2007

   URL: https://pubmed.ncbi.nlm.nih.gov/17916231

4. Immunogenicity and Antibody Development: Dressler D, Benecke R. "Antibody-induced botulinum toxin deficiency." Journal of Neurology. 2007;254(9):1110-1114. PMID: 17431705.

   Title: Neutralizing Antibody Formation in Botulinum Toxin Treatment

   Authors: Dressler D, Benecke R.

   Publisher: Journal of Neurology

   Year: 2007

   URL: https://pubmed.ncbi.nlm.nih.gov/17431705

5. Room Temperature Stability: Merz Pharmaceuticals GmbH. “Xeomin (incobotulinumtoxin A) — Stability Data and Storage Conditions.” Technical Documentation; 2020.

   Title: Xeomin Thermal Stability and Room Temperature Storage

   Publisher: Merz

   Year: 2020

   URL: https://www.merz.com/en

6. EMA Approval History: European Medicines Agency. “Bocouture—Assessment Report (CPMP).” EMA/CHMP; 2005.

   Title: European Medicines Agency Approval of Incobotulinumtoxin A (Bocouture)

   Publisher: EMA

   Year: 2005

   URL: https://www.ema.europa.eu

7. Carruthers 5-Point Glabellar Technique: Carruthers JD, Carruthers JA. "Rating the Severity of Facial Wrinkles: Implications for Treatment." Dermatologic Surgery. 1997;23(7):613-618. PMID: 9255644.

   Title: The Carruthers 5-Point Glabellar Injection Technique

   Authors: Carruthers JD, Carruthers JA.

   Publisher: Dermatologic Surgery

   Year: 1997

   URL: https://pubmed.ncbi.nlm.nih.gov/9255644

8. Botulinum Toxin Mechanism of Action — Comprehensive Review: Jankovic J. "Botulinum Toxin in Clinical Practice." Journal of Neurology, Neurosurgery & Psychiatry. 2004;75(7):951-957. PMID: 15201348.

   Title: Botulinum Toxin Mechanism and Clinical Applications

   Authors: Jankovic J.

   Publisher: Journal of Neurology, Neurosurgery & Psychiatry

   Year: 2004

   URL: https://pubmed.ncbi.nlm.nih.gov/15201348

Last update: April 22, 2026 · Medical editor: Dr. Hamza Gemici